ReviewCurrent opinion in nephrology and hypertension2014
Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.
Review in Current opinion in nephrology and hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.BMC nephrology · 2022Pooled it
- I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology.Jornal brasileiro de nefrologiaGuideline
- Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment.Circulation · 2020Trial
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Review
- Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026Review
- Comparative cardiovascular outcomes of renin-angiotensin system inhibitors in patients receiving maintenance hemodialysis: a large real-world cohort study.Frontiers in pharmacology · 2026Article
- Imaging of Congestion in Cardio-renal Syndrome.Current heart failure reports · 2025Review
- Value of two-dimensional speckle-tracking echocardiography in the assessment of left atrial function in patients with chronic kidney disease.Quantitative imaging in medicine and surgery · 2025Article
- The cardiovascular unphysiology of thrice weekly hemodialysis.Current opinion in nephrology and hypertension · 2025Review
- Association between Visit-to-Visit Ultrafiltration Volume Variability, Vascular Biomarkers and Cardiovascular Parameters in Chronic Hemodialysis Patients.Journal of clinical medicine · 2024Article
- Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD.Kidney international reports · 2022Article
- Impact of left ventricular hypertrophy on clinical outcomes in patients with dialysis: a single-center study in Japan.Journal of medical ultrasonics (2001) · 2022Article
- Echocardiographic left ventricular hypertrophy and geometry in Chinese chronic hemodialysis patients: the prevalence and determinants.BMC cardiovascular disorders · 2022Observational
- Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients.Journal of nephrology · 2022Article
- The roles of sodium and volume overload on hypertension in chronic kidney disease.Kidney research and clinical practice · 2021Article
- Impact of parathyroidectomy on left ventricular function in end stage renal disease patients.BMC nephrology · 2020Article
- Characteristics of patients at initiation of renal replacement therapy - experience of a hemodialysis center.Experimental and therapeutic medicine · 2020Article
- Cardiovascular Functional Changes in Chronic Kidney Disease: Integrative Physiology, Pathophysiology and Applications of Cardiopulmonary Exercise Testing.Frontiers in physiology · 2020Review
- Atherosclerotic vascular disease is more prevalent among black ESKD patients on long-term CAPD in South Africa.BMC nephrology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewLeft ventricular hypertrophy (LVH) is common in end-stage renal disease (ESRD) and has been advocated as a therapeutic target. We review the considerations for targeting LVH as a modifiable risk factor in ESRD. RECENT
findingsPathologic myocardial changes underlying LVH provide an ideal substrate for the spread of arrhythmia and may be key contributors to the occurrence of sudden death in ESRD. LVH is present in 68-89% of incident hemodialysis patients and is frequently progressive, although regression is observed in a minority of patients. Higher degrees of baseline LVH, as well as greater increases in left ventricular mass index over time, are associated with decreased survival, but whether these associations are causal remains uncertain. Several interventions, including angiotensin blockade and frequent dialysis, can reduce the left ventricular mass index, but whether this is associated with improved survival has not been definitively demonstrated. SUMMARY: LVH is a highly prevalent and reversible risk factor, which holds promise as a novel therapeutic target in ESRD. Interventional trials are needed to provide additional evidence that LVH regression improves survival before prevention and reversal of LVH can be definitively adopted as a therapeutic paradigm in ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.